These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2874535)

  • 21. Anxiety, anxiolytics and brain stimulation reinforcement.
    Liebman JM
    Neurosci Biobehav Rev; 1985; 9(1):75-86. PubMed ID: 2858083
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A search for a new anticonvulsant and anxiolytic benzodiazepine devoid of side effects and tolerance liability.
    Costa E; Auta J; Caruncho H; Guidotti A; Impagnatiello F; Pesold C; Thompson DM
    Adv Biochem Psychopharmacol; 1995; 48():75-92. PubMed ID: 7653327
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacology of the pyrazolo-type compounds: agonist, antagonist and inverse agonist actions.
    Bennett DA
    Physiol Behav; 1987; 41(3):241-5. PubMed ID: 2893398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: behavioral studies with pigeons.
    Zhang L; Barrett JE
    Biol Psychiatry; 1990 May; 27(9):953-67. PubMed ID: 1970744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol.
    Seppälä T; Palva E; Mattila MJ; Korttila K; Shrotriya RC
    Psychopharmacology (Berl); 1980; 69(2):209-18. PubMed ID: 6109345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular aspects of the action of benzodiazepine and non-benzodiazepine anxiolytics: a hypothetical allosteric model of the benzodiazepine receptor complex.
    Williams M
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(2):209-47. PubMed ID: 6146163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of bipathic effect of phenazepam.
    Epstein OI; Voronina TA; Molodavkin GM; Belopol'skaya MV; Kheyfets IA; Dugina JL; Sergeeva SA
    Bull Exp Biol Med; 2007 Oct; 144(4):536-8. PubMed ID: 18642707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacological properties of the imidazobenzodiazepine, FG 8205, a novel partial agonist at the benzodiazepine receptor.
    Tricklebank MD; Honoré T; Iversen SD; Kemp JA; Knight AR; Marshall GR; Rupniak NM; Singh L; Tye S; Watjen F
    Br J Pharmacol; 1990 Nov; 101(3):753-61. PubMed ID: 1963808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discriminative stimulus effects of atypical anxiolytics in baboons and rats.
    Ator NA; Griffiths RR
    J Pharmacol Exp Ther; 1986 May; 237(2):393-403. PubMed ID: 2871171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice.
    Fernandez SP; Mewett KN; Hanrahan JR; Chebib M; Johnston GA
    Neuropharmacology; 2008 Oct; 55(5):900-7. PubMed ID: 18657554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Behavioral effects of opioid subtypes compared with benzodiazepines in the staircase paradigm.
    Milman A; Weizman R; Rigai T; Rice KC; Pick CG
    Behav Brain Res; 2006 Jun; 170(1):141-7. PubMed ID: 16574254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi.
    Hui KM; Huen MS; Wang HY; Zheng H; Sigel E; Baur R; Ren H; Li ZW; Wong JT; Xue H
    Biochem Pharmacol; 2002 Nov; 64(9):1415-24. PubMed ID: 12392823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of discriminative stimuli produced by full and partial benzodiazepine agonists: pharmacological specificity.
    Bennett DA
    Psychopharmacol Ser; 1988; 4():85-94. PubMed ID: 2899320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.
    Rundfeldt C; Socała K; Wlaź P
    J Neural Transm (Vienna); 2010 Nov; 117(11):1319-25. PubMed ID: 20967473
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone.
    Horváth K; Andrási F; Botka P; Hámori T
    Acta Physiol Hung; 1992; 79(2):153-61. PubMed ID: 1363928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Animal models of anxiety and the development of novel anxiolytic drugs.
    Sanger DJ; Perrault G; Morel E; Joly D; Zivkovic B
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(2):205-12. PubMed ID: 1678541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.
    Artaiz I; Romero G; Zazpe A; Monge A; Calderó JM; Roca J; Lasheras B; Del Río J
    Psychopharmacology (Berl); 1995 Jan; 117(2):137-48. PubMed ID: 7753959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?
    Savić MM; Huang S; Furtmüller R; Clayton T; Huck S; Obradović DI; Ugresić ND; Sieghart W; Bokonjić DR; Cook JM
    Neuropsychopharmacology; 2008 Jan; 33(2):332-9. PubMed ID: 17392731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofisopam and midazolam: differences in clinical effects and in changes of CSF monoamine metabolites.
    Hovi-Viander M; Kanto J; Scheinin H; Scheinin M
    Br J Clin Pharmacol; 1985 Nov; 20(5):492-6. PubMed ID: 2416331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buspirone, a novel nonbenzodiazepine anxiolytic.
    Kastenholz KV; Crismon ML
    Clin Pharm; 1984; 3(6):600-7. PubMed ID: 6150781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.